التفاصيل البيبلوغرافية
| العنوان: |
Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR) |
| المؤلفون: |
John Amerena, Mike K. Palmer, Sam S Miller, Jean-Pierre Bassand, Hugo R Hernández García, Brian S Bryzinski, Froukje Sosef, Michael Clearfield |
| المصدر: |
Trials, Vol 7, Iss 1, p 35 (2006)
Trials |
| بيانات النشر: |
Springer Nature |
| مصطلحات موضوعية: |
lcsh:R5-920, medicine.medical_specialty, Apolipoprotein B, biology, business.industry, Research, Atorvastatin, nutritional and metabolic diseases, Medicine (miscellaneous), Type 2 diabetes, medicine.disease, Gastroenterology, Internal medicine, biology.protein, medicine, Rosuvastatin, lipids (amino acids, peptides, and proteins), Pharmacology (medical), lcsh:Medicine (General), Prospective cohort study, business, Adverse effect, National Cholesterol Education Program, Rhabdomyolysis, medicine.drug |
| الوصف: |
Background Many patients at high risk of cardiovascular disease do not achieve recommended low-density lipoprotein cholesterol (LDL-C) goals. This study compared the efficacy and safety of low doses of rosuvastatin (10 mg) and atorvastatin (20 mg) in high-risk patients with hypercholesterolemia. Methods A total of 996 patients with hypercholesterolemia (LDL-C ≥ 3.4 and < 5.7 mmol/L [130 and 220 mg/dL]) and coronary heart disease (CHD), atherosclerosis, or a CHD-risk equivalent were randomized to once-daily rosuvastatin 10 mg or atorvastatin 20 mg. The primary endpoint was the percentage change from baseline in LDL-C levels at 6 weeks. Secondary endpoints included LDL-C goal achievement (National Cholesterol Education Program Adult Treatment Panel III [NCEP ATP III] goal < 100 mg/dL; 2003 European goal < 2.5 mmol/L for patients with atherosclerotic disease, type 2 diabetes, or at high risk of cardiovascular events, as assessed by a Systematic COronary Risk Evaluation (SCORE) risk ≥ 5% or 3.0 mmol/L for all other patients), changes in other lipids and lipoproteins, cost-effectiveness, and safety. Results Rosuvastatin 10 mg reduced LDL-C levels significantly more than atorvastatin 20 mg at week 6 (44.6% vs. 42.7%, p < 0.05). Significantly more patients achieved NCEP ATP III and 2003 European LDL-C goals with rosuvastatin 10 mg compared with atorvastatin 20 mg (68.8% vs. 62.5%, p < 0.05; 68.0% vs. 63.3%, p < 0.05, respectively). High-density lipoprotein cholesterol was increased significantly with rosuvastatin 10 mg versus atorvastatin 20 mg (6.4% vs. 3.1%, p < 0.001). Lipid ratios and levels of apolipoprotein A-I also improved more with rosuvastatin 10 mg than with atorvastatin 20 mg. The use of rosuvastatin 10 mg was also cost-effective compared with atorvastatin 20 mg in both a US and a UK setting. Both treatments were well tolerated, with a similar incidence of adverse events (rosuvastatin 10 mg, 27.5%; atorvastatin 20 mg, 26.1%). No cases of rhabdomyolysis, liver, or renal insufficiency were recorded. Conclusion In high-risk patients with hypercholesterolemia, rosuvastatin 10 mg was more efficacious than atorvastatin 20 mg at reducing LDL-C, enabling LDL-C goal achievement and improving other lipid parameters. Both treatments were well tolerated. |
| اللغة: |
English |
| تدمد: |
1745-6215 |
| DOI: |
10.1186/1745-6215-7-35 |
| URL الوصول: |
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1220c108c377fc7b6f49bd65cf596a12 |
| Rights: |
OPEN |
| رقم الانضمام: |
edsair.doi.dedup.....1220c108c377fc7b6f49bd65cf596a12 |
| قاعدة البيانات: |
OpenAIRE |